4859-06-7

Basic information

• Product Name: xylonidine
• Synonyms: xylonidine;N-(2,6-Dimethylphenyl)-4,5-dihydro-1H-imidazol-2-amine;NC-4;SKF-35886;St-95
• CAS NO: 4859-06-7
• Molecular Formula: C₁₁H₁₅N₃
• Molecular Weight: 0
• Mol File: 4859-06-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 290°C at 760 mmHg
• Flash Point: 129.2°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 0.00213mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: xylonidine(CAS DataBase Reference)
• NIST Chemistry Reference: xylonidine(4859-06-7)
• EPA Substance Registry System: xylonidine(4859-06-7)

Safety Data

• Hazardous Substances Data: 4859-06-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H15N3/c1-8-4-3-5-9(2)10(8)14-11-12-6-7-13-11/h3-5H,6-7H2,1-2H3,(H2,12,13,14)

Upstream product

• 5391-39-9 1-acetylimidazolidin-2-one 
• 87-62-7 2,6-dimethylaniline 
• 61939-98-8 2-[N-propargyl-N-(2',6'-dimethyl-phenyl)-amino]-2-imidazoline 
• 107-15-3 ethylenediamine 
• 19241-16-8 2,6-dimethylphenylisothiocyanate 

Relevant articles and documents

Method for treating central nervous system disorders with substituted 2-imidazoline derivatives

The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, X, A, and n are as defined in the specification and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms thereof.

Three-dimensional quantitative structure-activity studies of octopaminergic agonists responsible for the inhibition of sex-pheromone production in Hercoverpa armigera

The quantitative structure-activity relationship (QSAR) of octopaminergic agonists responsible for the inhibition of sex-pheromone production in Hercoverpa armigera, was analyzed using physicochemical parameters, molecular shape analysis (MSA), molecular field analysis (MFA), and receptor surface model (RSM), respectively. The dose-response studies were performed in vitro analyzing the effect of these compounds on intracellular cAMP production in the presence of pheromone biosynthesis activating neuropeptide (PBAN) at 1 pmol/intersegment. Six active derivatives were identified in the order of decreasing pheromonostatic activity: 2-(2,6- dimethylanilino)imidazolide (6) > 2-(2-methyl-4-chloroanilino)oxazolidine (1) > clonidine (5) > 2-(2,6-diethylanilino)thiazolidine (8) > 2-(3,5- dichlorobenzylamino)-2-oxazoline (4) > tolazoline (10) which were all active in the nanomolar range in inhibition of cAMP production by 1 pmol PBAN/intersegment. Four other compounds were less active having K(i) in the micromolar range. An MSA was tried to obtain QSAR equation that incorporates spatial molecular similarity data of those compounds. MFA on the training set of those compounds evaluated effectively the energy between a probe and a molecular model at a series of points defined by a rectangular or spherical grid. An RSM was generated using some subset of the most active structures. Three-dimensional energetics descriptors were calculated from RSM/ligand interaction and these three-dimensional descriptors were used in QSAR analysis. These results indicate that these derivatives could provide useful information in the characterization and differentiation of octopaminergic receptor types and subtypes. (C) 1999 Elsevier Science Ltd.

Propargyl-substituted 2-phenylamino-2-imidazolines and salts thereof

Compounds of the formula STR1 wherein R1, R2 and R3, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, methyl, ethyl, methoxy or trifluoromethyl, and R4 and R5 are each hydrogen or propargyl, but other than both hydrogen or both propargyl at the same time, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as the salts are useful as analgesics and hypotensives.